Latest Administration News

Allup Limited reports a challenging quarter with significant cash outflows from operations and investing, relying heavily on financing activities. The company is pursuing a $1.3 million entitlement issue to support ongoing feasibility work.

Northern Minerals Limited reported a $7.56 million net cash outflow from operating activities in the December 2024 quarter, offset by $28.5 million raised through borrowings, leaving a healthy cash balance of $35.76 million.

Prescient Therapeutics has secured FDA clearance to initiate its Phase 2 PTX-100 trial for relapsed cutaneous T-cell lymphoma, alongside progress in its cell therapy platforms and a solid cash position bolstered by a recent R&D rebate.

Titanium Sands Limited has made significant progress in securing its Industrial Mining License for the Mannar Project in Sri Lanka, while preparing for a crucial funding placement to support ongoing development.

Po Valley Energy Limited reports a robust December 2024 quarter marked by rising gas production, strong revenue growth, and significant progress in exploration and development across its Italian assets.

HeraMED reports a surge in its HeraCARE platform users and secures $4.1 million in new funding, underpinning its expansion in the US maternity care market and integration with major health systems.

Flynn Gold Limited has announced a maiden Exploration Target at its Golden Ridge Project in Tasmania, estimating up to 520,000 ounces of contained gold, alongside a new exploration licence near the Beaconsfield Gold Mine.

InFocus Group Holdings has marked a pivotal quarter with a major $2.5 million contract in digital gaming and a corporate rebrand signaling its shift to enterprise software and analytics. The imminent Prodigy9 acquisition and capital raise position the company for accelerated growth.

Coda Minerals has significantly enhanced the economic outlook of its Elizabeth Creek Copper-Cobalt Project, with a pre-tax NPV7 rising to $1.18 billion and a post-tax NPV7 increase of 57% to $802 million. The company also secured $5.1 million in fresh capital to accelerate exploration and drilling activities in 2025.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

Atrum Coal Limited reported a $1.25 million net cash outflow for the December 2024 quarter, driven by exploration and litigation expenses, while successfully raising $5.8 million through an equity entitlement issue.

Atrum Coal Limited has successfully raised A$5.8 million through an entitlement offer while advancing a significant legal claim against the Alberta government and negotiating the sale of its Canadian subsidiaries.